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ABSTRACT 
The present study was aimed at improving the aqueous solubility of candesartan cilexetil, a poorly water soluble drug, using poly ethylene glycol (PEG) 400 as 
co-solvent.  It  was  observed  that  use  of  5  %  PEG  400  as  co-solvent  significantly  improved  the  solubility  by  50  folds.  Beer’s  law  was  obeyed  in  the 
concentration range of 4-20 μg/mL. Regression value for the calibration curve at wave length 232 nm was close to 1. The analysis of tablets by the proposed 
method indicated good correlation between estimated and label claim. The results of recovery studies revealed that any small change in the drug concentration 
could be accurately determined by the proposed method. The low values of limit of detection (LOD) and limit of quantification (LOQ) of candesartan cilexetil 
in PEG 400 indicated good sensitivity of proposed method. As PEG 400 was cheaper and less toxic when compared to organic solvents, this can be used as a 
substitute for organic solvents in the analysis. Thus the method developed to improve aqueous solubility of poorly water soluble drugs was found to be 
economical, eco-friendly, accurate, precise and can be applied in the routine analysis of tablets. 
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INTRODUCTION  
Solubility  is  one  of  the  important  parameter  to  achieve 
desired  concentration  of  drug  in  systemic  circulation  for 
pharmacological  response  to  be  shown
1.  Poor  aqueous 
solubility  is  a  common  concern  in  the  pharmaceutical 
sciences,  and  several  pharmaceutical  researchers  have 
established methods for increasing the equilibrium solubility 
of  non–polar  drugs  in  aqueous  vehicles
2.  A  number  of 
methodologies can be adapted to improve  solubilization of 
poorly  water  soluble  drugs  and  further  to  improve  its 
bioavailability.  Commonly  employed  techniques  for 
solubilization include micronization, chemical modification, 
pH adjustment, solid dispersion, complexation, co-solvency, 
micellar  solubilization,  hydrotropy  etc
3.  Cosolvency  is  the 
addition of water miscible solvents to poorly water soluble to 
improve its aqueous solubility 
2. Poly ethylene glycol (PEG) 
has  been  used  to  modulate  the  water  solubility  of  poorly 
soluble  drugs
4,5.  PEG  with  a  molecular  weight  of  400 
(PEG400)  has  been  frequently  used  as  a  co-solvent  to 
dissolve poorly water-soluble drugs
6,7  Quantitative analysis 
of poorly water-soluble drugs involves use of various organic 
solvents  like  acetone,  chloroform,  dimethyl  formamide, 
ethanol,  methanol.  Drawbacks  of  organic  solvents  include 
their  toxicity,  higher  costs,  volatility  and  pollution
8,9.  The 
advantage of certain properties such as the solvent character 
being independent of pH, non-flammability, easy availability 
of  hydrotropes,  inexpensive  aqueous  phase  makes  this 
method  superior  to  other  solubilization  methods
10.  Weak 
electrolytes  and  nonpolar  molecules  have  poor  water 
solubility, which can be improved by altering polarity of the 
solvent system. This can be achieved by addition of another 
solvent. Co solvent system works by reducing the interfacial 
tension between the aqueous solution and hydrophobic solute 
i.e., solvent blending. Most co solvents have hydrogen bond 
donor and/or acceptor groups as well as small hydrocarbon 
regions
11. This mixed cosolvency technique is based on the 
principle  that  instead  of  using  one  solubilizer  in  large 
concentration  for  a  desired  level  of  solubility,  several 
solubilizers like hydrotropes (sodium ascorbate, urea, sodium 
benzoate), co-solvents (propylene glycol, PEG 200, 300, 400) 
and water soluble solids (PEG 4000, 6000, Cyclodextrins) in 
varying concentrations may be used that may show additive 
or synergistic enhancement in solubility.
12  Candesartan is a 
nonpeptide  angiotensin  II  blocker  used  as  an 
antihypertensive.  Candesartan  cilexetil,  a  white  crystalline 
powder with melting point 157-160 
0 is insoluble in water, 
soluble  in  methanol  and  is  administered  orally
13.  In  the 
present study, an attempt was made to increase the aqueous 
solubility of candesartan cilexetil using 5 % PEG 400 as a co-
solvent.  
MATERIALS AND METHOD 
Candesartan  cilexetil  bulk  drug  was  a  gift  sample  from 
Matrix laboratories, Hyderabad. PEG 400 was obtained from 
E.  Merck  (India)  limited,  Mumbai.  Tablets  of  candesartan 
cilexetil  were  purchased  from  local  market.  Shimadzu 
UV/Visible  recording  spectrophotometer  (model-UV-1601) 
with  1cm  matched  silica  cells  was  employed.  All  other 
chemicals and solvents used were of analytical grade.  
EXPERIMENTAL METHOD 
Saturation solubility studies of Candesartan cilexetil in 
PEG 400 
Solubility  of  candesartan  cilexetil  was  determined  by 
saturation  aqueous  solubility  method  in  co  -solvent 
containing 5% PEG 400 in distilled water. An excess amount 
of drug was added to 50ml beakers containing 50ml of 5 % 
PEG 400 in distilled water. The beakers were shaken for 12 
hours  at  28±10
0C.  The  solutions  were  filtered  through 
Whatman  filter  paper  #41,  and  the  resulting  filtrates  were 
suitably diluted and analyzed spectrophotometrically against 
solvent blank. 
Preparation of standard stock and calibration curve 
The  standard  stock  solution  of  candesartan  cilexetil  was 
prepared by dissolving 5 mg in 10ml of 5 % PEG 400. From 
this stock solution, 5ml of solution was diluted to 25 ml with Deveswaran Rajamanickam et al. IRJP 2012, 3 (5) 
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distilled  water  to  get  a  solution  containing  100μg/ml  and 
scanned in the entire UV range of 400-200 nm to determine 
the λ max of the drug. The λ max of candesartan cilexetil was 
found to be 232 nm. Five working standard solutions for the 
drug having concentration range of 4, 8, 12, 16 and 20 µg/ml 
was  prepared  with  distilled  water  from  the  stock  solution. 
The  absorbances  of  resulting  solutions  were  measured  at 
wavelength of 232 nm and a calibration curve was plotted to 
get the linearity and regression equation. 
Analysis of candesartan cilexetil in marketed tablets using 
5% PEG 400 
Ten tablets were weighed, powdered and powder equivalent 
to  4mg  of  candesartan  cilexetil  was  transferred  to  50ml 
volumetric flask containing 40ml of 5% PEG 400 in distilled 
water. The flasks were shaken for 20 mins to solubilize the 
drug  completely  and  volume  was  made  up  with  distilled 
water.  From  this  5ml  of  solution  was  pipetted  into  25  ml 
volumetric  flask  containing  distilled  water  to  obtain  a 
concentration  of  16  µg/ml.  The  absorbance  of  resulting 
solution was measured at 232 nm against solvent blank and 
drug content was calculated.  
Validation of the proposed method
13  
Recovery studies 
Tablet  powder  equivalent  to  4  mg  of  candesartan  cilexetil 
was transferred to a 100ml volumetric flask containing PEG 
400. 2mg of candesartan cilexetil bulk drug was added to the 
same volumetric flask. The flask was shaken for 20 mins to 
solubilize  the  drug.  Then  solution  was  filtered  through 
Whatmann  filter  paper  #41.  The  filtrate  was  diluted  with 
distilled water appropriately and absorbance was measured at 
232 nm against  corresponding  solvent  blank.  Drug  content 
was calculated and percent recovery was calculated. Similar 
procedure was adopted using 4 mg and 6 mg of candesartan 
cilexetil bulk drugs spiked concentration. The drug contents 
were determined and percent recoveries were estimated.  
Inter- day and Intra- day precision 
The  intra-day  concentration  of  the  drug  was  calculated  by 
measuring the absorbances of the working standard solutions 
on the same day at an interval of one hour, whereas the inter 
day concentration of drug was calculated on three different 
days within the laboratory conditions.  
Linearity 
The  absorbances  of  appropriate  dilutions  of  standard  stock 
solutions  were  measured  as  per  the  developed  method  to 
confirm the linearity.  
Limit  of  detection  (LOD)  and  Limit  of  Quantitation 
(LOQ) 
The LOD and LOQ of candesartan cilexetil by the proposed 
method  were  determined  using  calibration  standards.  LOD 
and LOQ were calculated as 3.3σ /S and 10σ/S, respectively, 
where  S  is the  slope  of  the  calibration  curve  and σ is  the 
standard deviation of response. 
RESULTS AND DISCUSSION 
The  results  of  saturation  solubility  studies  of  candesartan 
cilexetil  indicated  that  there  was  increase  in  solubility  of 
candesartan cilexetil in water due to addition of co-solvent 
PEG 400 by 50 folds. Solubility of candesartan cilexetil in 
water was found to be 0.012mg/mL, which was significantly 
improved in the presence of 5% PEG 400 and was found to 
be 0.6mg/mL. Beer- Lambert’s range for candesartan cilexetil 
in  solution  employing  5  %  PEG  400  as  co-solvent  was 
between 4-20µg/mL. Spectrum analysis was done and λ max 
was found to be 232 nm (Fig. 1). Regression value for the 
calibration  curve  at  this  wave  length  was  0.9925  that  was 
close to 1, which indicated a good correlation between the 
amount estimated and the label claim.  The estimated label 
claim was found to be 101.3±0.864 with a standard error of 
0.436 (Table 1).  
This  revealed  that  use  of  PEG  400  as  co-solvent  will 
effectively  determine  the  drug  content  in  the  tablet 
formulation with out interference by UV analysis. To check 
drug stability and precipitation of drug in co-solvent, a part of 
solution  was  kept  in  room  temperature  for  48  hours.  The 
results revealed that estimation of candesartan cilexetil can be 
done  without  substantial  effect  on  drug  stability  as  no 
precipitation was observed. From this study it was obvious 
that  there  was  no  interference  of  5%  of  PEG  400  in 
estimation  of  candesartan  cilexetil  at  the  wavelength  of 
232nm. The results of recovery study revealed that any small 
change  in  the  drug  concentration  in  the  solution  could  be 
accurately  determined  by  the  proposed  method.  Accuracy, 
reproducibility and precision of the proposed methods were 
further  confirmed  by  percent  recovery  values,  which  were 
close  to  100,  with  low  values  of  standard  deviation  and 
standard  error  as  shown  in  Table  2.  Repeatability  results 
indicated the precision under the same operating conditions 
over  a  short  interval  time  and  inter-assay  precision. 
Intermediate  precision  study  expresses  within  laboratory 
variation  in  different  days.  In  both  intra  and  inter-day 
precision study for the method, co-efficients of variation were 
not more than 1.0% indicating good intermediate precision. 
The  low  values  of  LOD,  0.1355  μg/ml  and  LOQ,  0.4108 
μg/ml  for  candesartan  cilexetil  in  5%  PEG  400  indicated 
good sensitivity of proposed method (Table 3). It was thus 
concluded  that  solubilization  of  candesartan  cilexetil  using 
PEG  400  as  a  co-solvent  can  be  achieved.  By  this  new, 
simple,  accurate,  non-toxic,  cost-  effective  and  precise 
developed method, use of costlier, toxic organic solvents in 
the  analysis  can  be  minimized.  This  method  can  be 
successfully  employed  for  estimation  of  drugs  in  routine 
analysis of tablets. 
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Table 1: ANALYSIS OF TABLET FORMULATIONS OF CANDESARTAN CILEXETIL 
Tablet Formulation  Label Claim 
(mg) 
% Label claim Estimated
a 
 
Standard error 
Commercial tablet  with 5%  PEG 400 
(PEG)  4mg  101.3±0.864  0.436 
a  Mean±S.D (n=6) 
 
Table 2: RESULT OF RECOVERY STUDIES 
Formulation 
 
Amount of 
candesartan cilexetil 
tablet powder(mg) 
Amount of standard 
drug added (mg) 
Percent recovery 
estimated
a 
Standard error 
Commercial tablet with  
5 % PEG 400 
4  2  102.6 ± 0.638  0.314 
4  4  106.3 ± 0.826  0.418 
4  6  105.5 ± 0.964  0.458 
a  Mean±S.D (n=6) 
 
Table 3: OPTICAL CHARACTERISTICS DATA AND VALIDATION PARAMETERS 
Parameters  Values of candesartan cilexetil in 5 % PEG 400 
Working λmax (nm)  232 
Beer’s law limit (μg/ml)  4 – 20 
Molar Absorptivity  3.928×10
3 
Correlation coefficient
 a  0.9925 
Intercept
a  0.0041 
Slope
a  0.0058 
LOD
a   (μg/ml)  0.1355 
LOQ
a (μg/ml)  0.4108 
Intra-day
 a (precision) 
(Co-eff. of variation) 
0.425 
Inter-day
 a  ( precision) 
(Co-eff. of variation) 
0.2175 
Robustness  Robust 
a  n = 6 
 
 
 
Figure 1 : UV- SPECTRUM OF CANDESARTAN CILEXETIL IN 5 % PEG 400 
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